letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...3233343536373839404142...100101»
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Short-term preoperative endocrine therapy allows to estimate and revert patient prognosis with further treatment plan correction in HR+ HER2- early breast cancer patients. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_5949;    
    HR+ HER2- BC pts stages I-II any level of Ki67 independent from grade have received P-ET (letrozole (L)/anastrozole (A)/tamoxifen (TAM)) no less than 2 weeks until surgery in MCSC named after A.S. Loginov. In HR+ HER2- early BC pts short-term P-ET simply allows to estimate pts prognosis and further AT strategy proper planning: to identify the pts population of whom CT can be avoided while maintaining treatment efficacy with a better quality of life (42% pts of IIT) (1), to radically change the planned AT to achieve optimal treatment results (2,4% pts of IIT) (2).
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg., exemestane / Generic mfg.
    Polypharmacy and premature aromatase inhibitor (AI) discontinuation in older women with breast cancer. (Available On Demand; 351) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_4743;    
    P=N/A
    Increased prescription medication usage at AI initiation was associated with decreased risk of premature discontinuation of AI. Further research is needed to evaluate this interaction and identify characteristics that impact AI persistence in older women with breast cancer.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data. (Available On Demand; 429) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1138;    
    Updated data will be presented. The findings in this study highlight trends for selected AEs with various AI regimens, provide further insights, and help guide therapeutic decisions for patients with HRPBC.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Letrozole promotes the expression of integrin αvβ3 and HOXA10 in endometrium of endometriosis. (Pubmed Central) -  Apr 27, 2022   
    Animals were treated with letrozole at 2ug/kg of body weight, intragastric administration for 15 consecutive days. Letrozole increased the expression of αvβ3 and HOXA10 in the endometriosis model and endometrial receptivity.Abbreviations: WOI: window of implantation; RGD: Arg-Gly-Asp; HOX: homeobox; E2: estradiol; SPF: specific pathogen-free.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg.
    Journal, Monotherapy:  Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma. (Pubmed Central) -  Apr 26, 2022   
    No evident difference was observed in 1-, 3-, or 5-year survival rates between the two groups, while the 3-5-year recurrence rate was obviously lower, and the improvement of blood lipid indices was significantly better in the research group compared with the control group. LTZ alone or in sequence with TAM is effective and safe for the treatment of BC, which can significantly improve the prognosis and blood lipid indices of BC patients.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Letrozole Versus Hormonal Preparation in Frozen Cycles of PCOS Patients. (clinicaltrials.gov) -  Apr 26, 2022   
    P4,  N=236, Not yet recruiting, 
    LTZ alone or in sequence with TAM is effective and safe for the treatment of BC, which can significantly improve the prognosis and blood lipid indices of BC patients. Trial completion date: Nov 2023 --> Apr 2024 | Initiation date: Feb 2022 --> Aug 2022 | Trial primary completion date: Sep 2023 --> Feb 2024
  • ||||||||||  letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Trial completion:  Pharmacokinetics and Hepatic Safety of EGCG (clinicaltrials.gov) -  Apr 25, 2022   
    P1,  N=36, Completed, 
    Trial completion date: Nov 2023 --> Apr 2024 | Initiation date: Feb 2022 --> Aug 2022 | Trial primary completion date: Sep 2023 --> Feb 2024 Recruiting --> Completed
  • ||||||||||  letrozole / Generic mfg.
    Biomarker, Retrospective data, Journal:  Utility of Blood Markers for Predicting Outcomes of Fertility Preservation in Patients With Breast Cancer. (Pubmed Central) -  Apr 23, 2022   
    In total, 91 patients with breast cancer who had undergone COS using a letrozole-combined gonadotropin-releasing hormone (GnRH) antagonist protocol before chemotherapy were enrolled retrospectively in a single tertiary hospital...Protocols to acquire more mature oocytes, such as the dual-trigger approach, could be recommended for patients with breast cancer with MPV<10.15. Furthermore, a higher dose of gonadotropins was considered to obtain more oocytes in patients with MPV/PC<0.41.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Assessment of Breast Cancer Management in Sub-Saharan Africa. (Pubmed Central) -  Apr 22, 2022   
    Socioeconomic and cultural barriers and system delays persist. Workforce expansion must be prioritized to improve quality of care to improve outcomes.
  • ||||||||||  Management of the Side Effect of Hormone Therapy () (RM 3(Walker Hall 1)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_186;    
    This is crucial to increase treatment adherence and quality of life during adjuvant endocrine therapy. An individualized approach when choosing an intervention to control these symptoms is likely to have better chances of achieving a positive effect on oncological outcomes and quality of life.
  • ||||||||||  Must-have Knowledge about GnRH Agonist for Patients with Breast Cancer (RM 5(Art Hall)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_164;    
    In the light of increased morbidity with aromatase inhibitors and in the context of the reported data of the SOFT/TEXT trials, most patients are optimally treated with tamoxifen and ovarian function suppression (OFS). However, the option of aromatase inhibitors and OFS should be discussed on an individual basis.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Verzenio, Potent CDK4/6 Inhibitor, How to Optimize HR+/HER2- mBC Patient with CDK4/6 Inhibitors (RM 1(Vista 1+2)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_145;    
    The median PFS, the primary endpoint of the study, showed a statistically significant difference (p= 0.00021) with a hazard rate of 0.54 (95% CI: 0.41 to 0.72), demonstrating the efficacy of the drug.The Monarch 2 trial also evaluated the efficacy of abemaciclib combined with fulvestrant in patients with advanced BC which progressed despite hormone therapy...Furthermore, at our hospital we have established a patient support center providing easy access to outpatient counseling by nurses with relevant expertise, peer support from other breast cancer patients, and counseling by clinical psychologists to address the various psychological, social, and physical issues that may arise during treatment for advanced breast cancer.The present seminar will cover the history of the development of cancer treatments in Japan, introduce data from the Monarch 2 and 3 clinical trials, review cases of abemaciclib use in actual clinical practice, and examine how we deal with side effects in our practice. I would also be happy to share with our Korean colleagues the evaluation of abemaciclib in Japan and discuss the measures implemented against its various adverse effects.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Maximizing Clinical Outcome in HR+HER2- Metastatic Breast Cancer Patients: Palbociclib & CDK4/6 Inhibitors in Real-world Practice (RM 1(Vista 1+2)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_42;    
    Median OS was not reached in Palbociclib+letrozole arm while letrozole showed mOS of 43.1 month (HR= 0.66; 95% CI 0.53-0.82, P= 0.0002). In the real-world setting, palbociclib showed its efficacy in heterogeneous populations.3)In addition, palbociclib is the only CDK4/6 inhibitor that was approved for male breast cancer patients with HR(+) advanced breast cancer based on real-world data.In summary, palbociclib in combination with endocrine therapy is an effective and safe treatment option in patients with HR(+) advanced breast cancer with various co-morbidities in real-world practice.
  • ||||||||||  Trials of ER(+) Cancer in Japan (RM 5(Art Hall)) -  Apr 22, 2022 - Abstract #GBCC2022GBCC_36;    
    Unfortunately, this study was stopped due to safety concern, mainly liver toxicities and interstitial lung disease.From now on, both escalation and de-escalation are important if we select appropriate patients. Individualization is most essential, and we need to conduct clinical trials to answer many clinical questions.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (clinicaltrials.gov) -  Apr 22, 2022   
    P2,  N=198, Recruiting, 
    Individualization is most essential, and we need to conduct clinical trials to answer many clinical questions. Trial completion date: Jan 2023 --> Apr 2023 | Trial primary completion date: Aug 2022 --> Nov 2022
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Clinical, Journal:  Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. (Pubmed Central) -  Apr 21, 2022   
    We present here an assay suitable for the simultaneous measurement of serum levels of all third-generation AIs and ultra-low levels of estrogens, providing a powerful new tool to study drug efficacy and compliance. The method is highly valuable for postmenopausal patients whose pretreatment estradiol levels are below the threshold of detection for most routine assays, but still require suppression.
  • ||||||||||  letrozole / Generic mfg., spironolactone / Generic mfg.
    Journal:  Female Pelvic Conditions: Polycystic Ovary Syndrome. (Pubmed Central) -  Apr 21, 2022   
    Gonadotropin-releasing hormone analogues also are used to induce ovulation. (This is an off-label use of letrozole and gonadotropin-releasing hormone analogues.).
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
    Clinical, Retrospective data, Journal:  Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. (Pubmed Central) -  Apr 20, 2022   
    Older monotherapies that continue to be used in RCTs in comparator groups, such as anastrozole (251 of 252) and letrozole (252), fell to the bottom of the rankings...In this network meta-analysis study, combination therapies appeared to be associated with better outcomes than monotherapies in the treatment of HR-positive, ERBB2-negative MBC. These findings suggest that IT-NMA is a promising method for longitudinal ranking of anticancer regimens from RCTs with different end points, sparse interconnectivity, and decades-long timeframes.